Basel Medical Group Ltd shares surge 24.85% intraday after Roche's fenebrutinib shows promising results in Phase II trials.
ByAinvest
Friday, May 30, 2025 2:16 pm ET1min read
BMGL--
Basel Medical Group Ltd. surged 24.85% intraday, with Roche's fenebrutinib showing promising results in Phase II studies for relapsing multiple sclerosis, maintaining no disability progression and low levels of disease activity for up to two years. Phase III studies for fenebrutinib in relapsing and primary progressive multiple sclerosis are expected to start reading out at year end.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet